Xencor schedules XmAb819 webcast: Wells Fargo targets Xencor stock at USD 30

Published on 10/20/2026 at 13:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xencor stock costs EUR 20.50 on October 20, 2026. XmAb819 results are due October 25 and a webcast follows October 26.

Clinical timetable and finances

Xencor scheduled a 7:00 a.m. EDT webcast for October 26, 2026.
Second-quarter 2026 revenue reached USD 51.22 million.
Xencor stock trades at EUR 20.50 at 1:29 p.m. CEST at Lang & Schwarz on October 20, 2026.

XNCR, US98401F1057, Illustration mit AI erstellt.

Xencor (US98401F1057) will host an October 26, 2026 webcast on Phase 1 results for XmAb819, an experimental bispecific antibody for advanced clear cell renal cell carcinoma, Business Wire reported on October 19, 2026. The webcast is scheduled for 7:00 a.m. EDT and follows an oral presentation of the same program at the European Society for Medical Oncology Congress.

XmAb819 sets the next catalyst

The clinical timetable gives Xencor two closely spaced milestones. The company plans to present Phase 1 results on October 25, 2026, with intravenous dosing data intended to support selection of a recommended dose for a planned Phase 3 study. Xencor also plans to start a registration-enabling monotherapy study in advanced clear cell renal cell carcinoma in 2027, according to Business Wire.

What does the timetable mean?

The answer depends on whether the data can support dose selection and a later pivotal study. Expansion cohorts are evaluating intravenous doses, while subcutaneous dose escalation is ongoing. A sub-study for additional ENPP3-positive tumors opened in the second quarter of 2026, and another for patients who progressed after first-line immunotherapy opened in the third quarter of 2026, the company said through Business Wire.

Three dated Xencor milestones

On August 5, 2026, Xencor reported second-quarter financial results, with revenue of USD 51.22 million and a GAAP net loss of USD 21.73 million, according to Markets Insider. On October 15, 2026, Wells Fargo maintained a Buy rating and a USD 30.00 price target, also reported by Markets Insider. On October 19, 2026, Xencor scheduled the XmAb819 data webcast for October 26.

Dates for the clinical readout

The next two substantiated dates are October 25, 2026, for the ESMO oral presentation, and October 26, 2026, for the Xencor webcast. Both events concern XmAb819 and its potential path toward a Phase 3 study.

Stock price and company scale

Xencor was valued at USD 1.7 billion on October 19, 2026, while its Nasdaq price closed at USD 23.19 that day. The primary-exchange 52-week range was USD 10.38 to USD 30.61 on that date. The company develops engineered antibodies for cancer and autoimmune diseases and has more than 20 candidates in clinical development.

Xencor was trading at EUR 20.50 at Lang & Schwarz on October 20, 2026 at 1:29 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Xencor stock.